.jpg)
1 hour ago
3
Article content
Shares of companies involved in psychedelic-related therapies are surging in premarket trading Monday after U.S. President Donald Trump signed an executive order to expedite research and access.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
U.S.-traded shares of Compass Pathways Plc spiked as much as 39 per cent before the market open while AtaiBeckley Inc. surged 32 per cent. Definium Therapeutics, Inc. rallied 27 per cent and GH Research PLC jumped 20 per cent.
Article content
Article content
Article content
The new order directs the U.S. Food and Drug Administration to issue expedited review vouchers to psychedelics with a so-called breakthrough designation, shortening the review time to one to two months from six to ten months. AtaiBeckley, Definium and Compass Pathways all have therapies with breakthrough designation status.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
For Wall Street, the latest development marks a turning point for the industry that’s long waited for a breakout moment. Analysts see the support for psychedelics from the highest level of the U.S. government as helping to ease approval pathway for drug developers.
Article content
The signing of the order is “a substantial step towards diminishing regulatory risk in this emerging class of therapies, enabling investor comfort,” RBC Capital Markets analyst Brian Abrahams wrote in a note to clients. “While not explicitly recommending psychedelics, the nature of the executive order strongly suggests a broad openness to psychedelics.”
Article content
Trump’s order also directed the FDA to give new guidance to researchers on ibogaine, a psychedelic compound extracted from the iboga plant in Africa that’s used to treat depression, anxiety and post-traumatic stress disorder for military veterans. While the order doesn’t reclassify the drug for medical use, Trump urged the health professionals to reclassify it quickly.
Article content
The industry faced a setback in 2024 when U.S. regulators rejected an MDMA-assisted therapy for PTSD from Lykos Therapeutics Inc., citing the quality of research and questions over the clinical trial design.
Article content
“With several executive branches aligned, investor mindshare should rise meaningfully ahead of potential approvals in 2027-2030,” Jefferies analyst Andrew Tsai wrote in a note.
Article content
Article content
English (US)